Edition:
United States

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

16.42USD
1:15pm EDT
Change (% chg)

$0.30 (+1.86%)
Prev Close
$16.12
Open
$16.40
Day's High
$16.48
Day's Low
$16.05
Volume
127,253
Avg. Vol
543,797
52-wk High
$27.50
52-wk Low
$8.00

Select another date:

Wed, May 16 2018

BRIEF-Bioverativ And Sangamo Announce FDA Acceptance Of Ind Application For Gene-Edited Cell Therapy BIVV003

* BIOVERATIV AND SANGAMO ANNOUNCE FDA ACCEPTANCE OF IND APPLICATION FOR GENE-EDITED CELL THERAPY BIVV003 TO TREAT SICKLE CELL DISEASE

BRIEF-Sangamo Therapeutics Reports Q1 Loss Per Share Of $0.23

* SANGAMO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Sangamo Therapeutics Prices Public Offering Of Common Stock

* SANGAMO THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Sangamo Therapeutics Proposes Public Offering Of Common Stock

* SANGAMO THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Sangamo Therapeutics Files For Potential Mixed Shelf Offering

* SANGAMO THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text (https://bit.ly/2vH7vVF) Further company coverage:

BRIEF-Sangamo Therapeutics Says Co Announced A Data Security Incident Involving Compromise Of A Senior Executive's Company Email Account

* SANGAMO THERAPEUTICS SAYS ON APRIL 17, CO ANNOUNCED A DATA SECURITY INCIDENT INVOLVING COMPROMISE OF A SENIOR EXECUTIVE'S COMPANY EMAIL ACCOUNT

Sangamo in $3 billion gene-editing deal with Gilead

U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.

UPDATE 2-Sangamo in $3 billion gene-editing deal with Gilead

* Sangamo stock jumps 21 percent (Adds CEO and executive quotes, background, updates share price)

Gilead signs $3 bln licensing deal for Sangamo's gene-editing platform

Feb 22 Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology platform to develop cancer treatments, in a collaboration deal worth more than $3 billion, the two companies said on Thursday.

BRIEF-Sangamo Therapeutics Q4 Loss Per Share $0.15

* SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Select another date: